Summary

A randomized, double-blind, multicenter study demonstrated that a G-protein-coupled receptor 40 (GPR40) agonist had glucose-lowering efficacy for the treatment of type 2 diabetes. The novel agent significantly reduced HbA1C compared with placebo, with efficacy that was comparable with glimepiride but with a significantly lower rate of hypoglycemia.